The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine
VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CNSX:CMND.CN), (OTCPink:CMNDF), (FSE:CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
Read more at globenewswire.com